OptiMalVax: Optimizing A Deployable High Efficacy Malaria Vaccine
Funder
National Health and Medical Research Council
Funding Amount
$494,618.00
Summary
In this proposal, a consortium comprising many of the leading malariologists, vaccine researchers and product developers in Europe, USA, Australia and Africa will collaborate in an exciting programme of antigen discovery science linked to rapid clinical development of new vaccine candidates against malaria.
Hendra virus (HeV) cause a disease transmitted from bats to horses which in turn infect humans and other horses. There are no drugs or vaccines for HeV. Since humans are infected by inhalation, a vaccine that can generate antibody in the lung and protect from infection will be ideal. We have found that a natural sugar called mannan used with virus proteins and administered via the nostrils to generate such responses. In this project we will prepare this vaccine and use it in a mouse model of HeV ....Hendra virus (HeV) cause a disease transmitted from bats to horses which in turn infect humans and other horses. There are no drugs or vaccines for HeV. Since humans are infected by inhalation, a vaccine that can generate antibody in the lung and protect from infection will be ideal. We have found that a natural sugar called mannan used with virus proteins and administered via the nostrils to generate such responses. In this project we will prepare this vaccine and use it in a mouse model of HeV infection to see if it can protect the mice.Read moreRead less
A vaccine to prevent AIDS is urgently needed. The European Union recently awarded over 20 million euros to a European consortium, called EAVI2020, to advance multiple HIV vaccines into human testing. Five Australian HIV vaccine experts are named investigators on this award to provide advanced laboratory analyses and intellectual input into the 5 year program if this NHMRC-EU Collaborative Research Grant is successful.